title: Nonviral approaches for neuronal delivery of nucleic acids.
abstract: The delivery of therapeutic nucleic acids to neurons has the potential to treat neurological disease and spinal cord injury. While select viral vectors have shown promise as gene carriers to neurons, their potential as therapeutic agents is limited by their toxicity and immunogenicity, their broad tropism, and the cost of large-scale formulation. Nonviral vectors are an attractive alternative in that they offer improved safety profiles compared to viruses, are less expensive to produce, and can be targeted to specific neuronal subpopulations. However, most nonviral vectors suffer from significantly lower transfection efficiencies than neurotropic viruses, severely limiting their utility in neuron-targeted delivery applications. To realize the potential of nonviral delivery technology in neurons, vectors must be designed to overcome a series of extra- and intracellular barriers. In this article, we describe the challenges preventing successful nonviral delivery of nucleic acids to neurons and review strategies aimed at overcoming these challenges.
authors.affiliation: Bioengineering, University of Washington, Seattle, WA 98195, USA.
authors.forename: Jamie M
authors.initials: JM
authors.lastname: Bergen
authors.forename: In-Kyu
authors.initials: IK
authors.lastname: Park
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Horner
authors.forename: Suzie H
authors.initials: SH
authors.lastname: Pun
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000378:metabolism; D016503:Drug Delivery Systems; D005079:Excipients; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009474:Neurons / Q000502:physiology*; D009696:Nucleic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D014162:Transfection
chemical_list: D005079:Excipients; D009696:Nucleic Acids